- VRTX -0.80%
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Yahoo Finance · 5 days ago
Search results
Vertex Pharmaceuticals invests in scientific innovation to create transformative medicines for people with serious diseases.
- 468.72Add to watchlist-3.79 (-0.80%)At close: Fri. Jun 28, 2024 4:00 PM EDT · Nasdaq Real Time Price (USD) · Market closed
- Open473.21High477.31Low467.79
- Mkt Cap120.95BP/E (TTM)30.40Div & YieldN/A & N/A
- Prev. Close472.5152 Wk. Low335.8252 Wk. High486.43
Top storiesRelated stocks
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
Vertex Pharmaceuticals strikes at the core of serious diseases to change people's lives – learn about our mission, values and recognition.
Dec 8, 2023 · Vertex leads global development, manufacturing and commercialization of CASGEVY with support from CRISPR Therapeutics. In conjunction with the FDA approval of CASGEVY, Vertex will make a $200 million milestone payment to CRISPR, which will be capitalized and amortized to cost of sales.
Jul 11, 2022 · Vertex’s VX-880, an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy for T1D, has already achieved proof-of-concept with highly promising safety and efficacy results from an ongoing Phase 1/2 study which continues to enroll and dose patients.
Latest Press Releases. Jun 21 2024. Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions. Read More.
